Results 101 to 110 of about 813,020 (358)

COST-BENEFIT ANALYSIS – A HELPFUL INSTRUMENT FOR THE ABSORPTION VALUATION OF STRUCTURAL AND COHESION FUNDS IN ROMANIA [PDF]

open access: yes
Starting with the entering in European Union, absorption of structural and cohesion funds seemed to be a challenge for Romania. But unfortunately, after the first half of the programming period, cost-benefit analysis of projects from different ...
Ecaterina Mariana SUCIU   +3 more
core  

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

open access: yesMolecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung   +17 more
wiley   +1 more source

Evaluation of Cross-Border Leakages in Community Support Frameworks. The case of Andalusia (Spain). [PDF]

open access: yes
The enlargement of the European Union to 25 members implies that relative position of Andalusia will improve with regard to the new GDP per capita average.
Antonio Morillas   +2 more
core  

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Cost-Benefit Analysis - Economic Tool Used to Aid Decision-Making Regarding the Distribution of Public Funds [PDF]

open access: yes
After 1990, the financial analysis of the phenomena that occur in firms has grown in importance. Financial analysts face new challenges as a result of Romania’s joining to the European Union. A thorough analysis of the investment decisions is required in
Daniel CIRCIUMARU   +2 more
core  

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

open access: yesMolecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee   +8 more
wiley   +1 more source

Analysis of structural and cohesion funds absorption in Romania [PDF]

open access: yes
The present research aims at depicting the main drivers and bottlenecks in the process of structural and cohesion funds absorption in Romania. As these funds are important inflows for the Romanian economy it is highly important to have a clear picture of
Cristi SPULBAR   +2 more
core  

Taking stock of structural funds implementation : current challenges and future opportunities [PDF]

open access: yes, 2003
This paper highlights several themes which have informed programme management since IQ-Net meeting in June 2002, held in Lulea, Sweden. First, it provides an overview of the main development in programme implementation and the financial execution of ...
Bachtler, John   +2 more
core  

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy